| UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY |
|
|||||||
|
Kinase Fusion Gene:LPCAT3_MAP3K13 |
Kinase Fusion Protein Summary |
 Kinase Fusion gene summary |
| Kinase Fusion partner gene information | Kinase Fusion gene name: LPCAT3_MAP3K13 | KinaseFusionDB ID: KFG3198 | FusionGDB2.0 ID: KFG3198 | Hgene | Tgene | Gene symbol | LPCAT3 | MAP3K13 | Gene ID | 10162 | 9175 | |
| Gene name | lysophosphatidylcholine acyltransferase 3 | mitogen-activated protein kinase kinase kinase 13 | ||||||||||
| Synonyms | C3F|LPCAT|LPLAT 5|LPLAT12|LPSAT|MBOAT5|OACT5|nessy | LZK|MEKK13|MLK | ||||||||||
| Cytomap | 12p13.31 | 3q27.2 | ||||||||||
| Type of gene | protein-coding | protein-coding | ||||||||||
| Description | lysophospholipid acyltransferase 51-acylglycerophosphocholine O-acyltransferase1-acylglycerophosphoethanolamine O-acyltransferase1-acylglycerophosphoserine O-acyltransferaseO-acyltransferase (membrane bound) domain containing 5O-acyltransferase domai | mitogen-activated protein kinase kinase kinase 13leucine zipper-bearing kinasemixed lineage kinase | ||||||||||
| Modification date | 20240331 | 20240305 | ||||||||||
| UniProtAcc | Q6P1A2 | O43283 | ||||||||||
| Ensembl transtripts involved in fusion gene | ENST ids | ENST00000261407, ENST00000535021, | ENST00000438798, ENST00000446828, ENST00000448876, ENST00000454237, ENST00000265026, ENST00000424227, ENST00000443863, ENST00000535426, | |||||||||
| Context (manual curation of fusion genes in KinaseFusionDB) | PubMed: LPCAT3 [Title/Abstract] AND MAP3K13 [Title/Abstract] AND fusion [Title/Abstract] | |||||||||||
| Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0) | LPCAT3(7125578)-MAP3K13(185003305), # samples:2 | |||||||||||
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | LPCAT3 | GO:0036150 | phosphatidylserine acyl-chain remodeling | 18195019|18772128 |
| Hgene | LPCAT3 | GO:0036151 | phosphatidylcholine acyl-chain remodeling | 18195019|18772128 |
| Hgene | LPCAT3 | GO:0036152 | phosphatidylethanolamine acyl-chain remodeling | 18772128 |
| Tgene | MAP3K13 | GO:0006468 | protein phosphorylation | 9353328|11726277 |
| Tgene | MAP3K13 | GO:0007254 | JNK cascade | 9353328|11726277 |
| Tgene | MAP3K13 | GO:0046777 | protein autophosphorylation | 9353328 |
| Tgene | MAP3K13 | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 12492477 |
| Tgene | MAP3K13 | GO:0051403 | stress-activated MAPK cascade | 11726277 |
| Kinase Fusion gene breakpoints across LPCAT3 (5'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
| Kinase Fusion gene breakpoints across MAP3K13 (3'-gene) * Click on the image to open the UCSC genome browser with custom track showing this image in a new window. |
Top |
Kinase Fusion Gene Sample Information |
| Kinase Fusion gene information. |
| Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Sample | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp |
| ChimerDB4 | TCGA-BC-A10Y-01A | LPCAT3 | chr12 | 7125578 | MAP3K13 | chr3 | 185003305 |
Top |
Kinase Fusion ORF Analysis |
| Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB. |
| Henst | Tenst | Hgene | Hchr | Hbp | Tgene | Tchr | Tbp | Seq length (transcript) | Seq length (amino acids) |
Top |
Kinase Fusion Amino Acid Sequences |
| For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
| >Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq |
Multiple Sequence Alignment of All Fusion Protein Isoforms |
Top |
Kinase Fusion Protein Functional Features |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:7125578/:185003305) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| LPCAT3 | MAP3K13 |
| FUNCTION: Lysophospholipid O-acyltransferase (LPLAT) that catalyzes the reacylation step of the phospholipid remodeling process also known as the Lands cycle (PubMed:18782225, PubMed:18195019, PubMed:18772128). Catalyzes transfer of the fatty acyl chain from fatty acyl-CoA to 1-acyl lysophospholipid to form various classes of phospholipids. Converts 1-acyl lysophosphatidylcholine (LPC) into phosphatidylcholine (PC) (LPCAT activity), 1-acyl lysophosphatidylserine (LPS) into phosphatidylserine (PS) (LPSAT activity) and 1-acyl lysophosphatidylethanolamine (LPE) into phosphatidylethanolamine (PE) (LPEAT activity) (PubMed:18782225, PubMed:18195019, PubMed:18772128). Favors polyunsaturated fatty acyl-CoAs as acyl donors compared to saturated fatty acyl-CoAs (PubMed:18195019, PubMed:18772128). Has higher activity for LPC acyl acceptors compared to LPEs and LPSs. Can also transfer the fatty acyl chain from fatty acyl-CoA to 1-O-alkyl lysophospholipid or 1-O-alkenyl lysophospholipid with lower efficiency (By similarity). Acts as a major LPC O-acyltransferase in liver and intestine. As a component of the liver X receptor/NR1H3 or NR1H2 signaling pathway, mainly catalyzes the incorporation of arachidonate into PCs of endoplasmic reticulum (ER) membranes, increasing membrane dynamics and enabling triacylglycerols transfer to nascent very low-density lipoprotein (VLDL) particles. Promotes processing of sterol regulatory protein SREBF1 in hepatocytes, likely by facilitating the translocation of SREBF1-SCAP complex from ER to the Golgi apparatus (By similarity). Participates in mechanisms by which the liver X receptor/NR1H3 or NR1H2 signaling pathway counteracts lipid-induced ER stress response and inflammation. Down-regulates hepatic inflammation by limiting arachidonic acid availability for synthesis of inflammatory eicosanoids, such as prostaglandins (By similarity). In enterocytes, acts as a component of a gut-brain feedback loop that coordinates dietary lipid absorption and food intake. Regulates the abundance of PCs containing linoleate and arachidonate in enterocyte membranes, enabling passive diffusion of fatty acids and cholesterol across the membrane for efficient chylomicron assembly (By similarity). In the intestinal crypt, acts as a component of dietary-responsive phospholipid-cholesterol axis, regulating the biosynthesis of cholesterol and its mitogenic effects on intestinal stem cells (By similarity). {ECO:0000250|UniProtKB:Q91V01, ECO:0000269|PubMed:18195019, ECO:0000269|PubMed:18772128, ECO:0000269|PubMed:18782225}. | FUNCTION: Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B. {ECO:0000269|PubMed:11726277, ECO:0000269|PubMed:12492477, ECO:0000269|PubMed:9353328}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
| - Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt). |
| Partner | Hgeneene | Hbp | Tgeneene | Tbp | ENST | BPexon | TotalExon | Protein feature loci | BPloci | TotalLen | Feature | Note |
Top |
Kinase-Substrate Information of LPCAT3_MAP3K13 |
| Phosphorylation target of the kinase (phosphosite, 03-17-2024) |
| Kinase | Kinase UniProt Acc | Kinase species | Substrate | Substrate UniProt Acc | Substrate phosphorylated residues | Substrate phosphorylated sites (+/-7AA) | Domain |
| MAP3K13 | O43283 | human | TRIM25 | Q14258 | S12 | CPLAEELsCSICLEP |
| Biological Network Integration of This Kinase and Substrates (GeneMANIA website) |
| Enriched GO biological processes of the phosphorylation target genes of the kinase |
| Kinase | GOID | GO term | P.adjust |
| MAP3K13 | ID | Description | 0.00e+00 |
| MAP3K13 | GO:0044790 | suppression of viral release by host | 1.50e-02 |
| MAP3K13 | GO:0046597 | negative regulation of viral entry into host cell | 1.50e-02 |
| MAP3K13 | GO:1903901 | negative regulation of viral life cycle | 1.50e-02 |
| MAP3K13 | GO:0019076 | viral release from host cell | 1.50e-02 |
| MAP3K13 | GO:0035891 | exit from host cell | 1.50e-02 |
| MAP3K13 | GO:0033280 | response to vitamin D | 1.50e-02 |
| MAP3K13 | GO:0006513 | protein monoubiquitination | 1.50e-02 |
| MAP3K13 | GO:0140374 | antiviral innate immune response | 1.50e-02 |
| MAP3K13 | GO:0046596 | regulation of viral entry into host cell | 1.50e-02 |
| MAP3K13 | GO:0052372 | modulation by symbiont of entry into host | 1.54e-02 |
| MAP3K13 | GO:0043903 | regulation of biological process involved in symbiotic interaction | 1.58e-02 |
| MAP3K13 | GO:0043627 | response to estrogen | 1.58e-02 |
| MAP3K13 | GO:0030433 | ubiquitin-dependent ERAD pathway | 1.69e-02 |
| MAP3K13 | GO:0033273 | response to vitamin | 1.69e-02 |
| MAP3K13 | GO:0048525 | negative regulation of viral process | 1.70e-02 |
| MAP3K13 | GO:1990830 | cellular response to leukemia inhibitory factor | 1.70e-02 |
| MAP3K13 | GO:1990823 | response to leukemia inhibitory factor | 1.70e-02 |
| MAP3K13 | GO:0036503 | ERAD pathway | 1.70e-02 |
| MAP3K13 | GO:1903900 | regulation of viral life cycle | 1.85e-02 |
| MAP3K13 | GO:0002753 | cytosolic pattern recognition receptor signaling pathway | 1.85e-02 |
| MAP3K13 | GO:0051092 | positive regulation of NF-kappaB transcription factor activity | 1.85e-02 |
| MAP3K13 | GO:0007584 | response to nutrient | 1.85e-02 |
| MAP3K13 | GO:0046718 | viral entry into host cell | 1.85e-02 |
| MAP3K13 | GO:0044409 | entry into host | 1.85e-02 |
| MAP3K13 | GO:0050792 | regulation of viral process | 1.85e-02 |
| MAP3K13 | GO:0044000 | movement in host | 1.99e-02 |
| MAP3K13 | GO:0043123 | positive regulation of canonical NF-kappaB signal transduction | 2.00e-02 |
| MAP3K13 | GO:0051701 | biological process involved in interaction with host | 2.08e-02 |
| MAP3K13 | GO:0002221 | pattern recognition receptor signaling pathway | 2.22e-02 |
| MAP3K13 | GO:0051091 | positive regulation of DNA-binding transcription factor activity | 2.22e-02 |
| MAP3K13 | GO:0002758 | innate immune response-activating signaling pathway | 2.22e-02 |
| MAP3K13 | GO:0043122 | regulation of canonical NF-kappaB signal transduction | 2.22e-02 |
| MAP3K13 | GO:0034976 | response to endoplasmic reticulum stress | 2.22e-02 |
| MAP3K13 | GO:0002218 | activation of innate immune response | 2.24e-02 |
| MAP3K13 | GO:0007249 | canonical NF-kappaB signal transduction | 2.36e-02 |
| MAP3K13 | GO:0019058 | viral life cycle | 2.36e-02 |
| MAP3K13 | GO:0044403 | biological process involved in symbiotic interaction | 2.36e-02 |
| MAP3K13 | GO:0051607 | defense response to virus | 2.36e-02 |
| MAP3K13 | GO:0140546 | defense response to symbiont | 2.36e-02 |
| MAP3K13 | GO:0045089 | positive regulation of innate immune response | 2.36e-02 |
| MAP3K13 | GO:0030522 | intracellular receptor signaling pathway | 2.37e-02 |
| MAP3K13 | GO:0002833 | positive regulation of response to biotic stimulus | 2.42e-02 |
| MAP3K13 | GO:0006979 | response to oxidative stress | 2.54e-02 |
| MAP3K13 | GO:0051090 | regulation of DNA-binding transcription factor activity | 2.54e-02 |
| MAP3K13 | GO:0045088 | regulation of innate immune response | 2.56e-02 |
| MAP3K13 | GO:0016032 | viral process | 2.56e-02 |
| MAP3K13 | GO:0009615 | response to virus | 2.56e-02 |
| MAP3K13 | GO:0043161 | proteasome-mediated ubiquitin-dependent protein catabolic process | 2.63e-02 |
| MAP3K13 | GO:0002757 | immune response-activating signaling pathway | 2.65e-02 |
Top |
Related Drugs to LPCAT3_MAP3K13 |
| Drugs used for this fusion-positive patient. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Drug | Source | PMID |
| Distribution of the number of studies mentioning LPCAT3-MAP3K13 and kinase inhibitors the PubMed Abstract (04-01-2024) |
| Fusion gene - drug pair 1 | Fusion gene - drug pair 2 | PMID | Publication date | DOI | Study title |
Top |
Related Diseases to LPCAT3_MAP3K13 |
| Diseases that have this fusion gene. (Manual curation of PubMed, 04-30-2022 + MyCancerGenome) |
| Hgene | Tgene | Disease | Source | PMID |
| Related diseases from the literature mentioned this fusion gene and drug. (PubMed, 04-01-2024) |
| MeSH ID | MeSH term |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
Top |
Clinical Trials of the Found Drugs/Small Molecules |
| Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024) |
| Clinical Trials from clinicaltrials.gov (06-17-2024) |
| Fusion Gene | Kinase Inhibitor | NCT ID | Study Status | Phases | Disease | # Enrolment | Date |
Copyright 2024-Present -The University of Texas Health Science Center at Houston
Web File Viewing | Emergency Information |Campus Carry|Site Policies |